0001716110-17-000001.txt : 20170905 0001716110-17-000001.hdr.sgml : 20170904 20170905094345 ACCESSION NUMBER: 0001716110-17-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20170905 DATE AS OF CHANGE: 20170905 EFFECTIVENESS DATE: 20170905 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Antidote Therapeutics, Inc. CENTRAL INDEX KEY: 0001716110 IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-294019 FILM NUMBER: 171067582 BUSINESS ADDRESS: STREET 1: 708 QUINCE ORCHARD ROAD STREET 2: SUITE 250-C CITY: GAITHERSBURG STATE: MD ZIP: 20878 BUSINESS PHONE: 301-365-5385 MAIL ADDRESS: STREET 1: 708 QUINCE ORCHARD ROAD STREET 2: SUITE 250-C CITY: GAITHERSBURG STATE: MD ZIP: 20878 D 1 primary_doc.xml X0708 D LIVE 0001716110 Antidote Therapeutics, Inc. 708 QUINCE ORCHARD ROAD SUITE 250-C GAITHERSBURG MD MARYLAND 20878 301-365-5385 DELAWARE None None Corporation true 2013 Matthew W. Kalnik, PhD c/o Antidote Therapeutics, Inc. 708 Quince Orchard Road, Suite 250-C Gaithersburg MD MARYLAND 20878 Executive Officer Director Kenneth C. Carter 10316 Cavanaugh Court Rockville MD MARYLAND 20850 Director Biotechnology Decline to Disclose 06b false 2017-08-24 false true false 0 432341 432341 0 false 2 0 0 0 false Antidote Therapeutics, Inc. /s/ Matthew W. Kalnik, PhD Matthew W. Kalnik, PhD President & Chief Executive Officer 2017-08-31